

Summary

I have synthesized 27 novel derivatives of piperidine-indole with amide and urea linkage in the 1st chapter of this thesis. All compounds are characterized at NIH US in total 60 cell lines. In which Compound **9c**, **11d**, **13b**, and **13e** had noteworthy anticancer effects against kidney cancer (UO-31). Compound **11f** demonstrated noteworthy anticancer action against breast cancer (MDA-MB-468) and leukemia (RPMI-8286), with inhibition levels indicating their potential for therapeutic use. While compound **9j** (SNB-75) had efficacy against CNS cancer. All 27 compounds are characterised by TLC, LC-MS, ¹H NMR, ¹³C NMR, IR, Elemental analysis and Melting point.

I have synthesized 14 novel derivatives of piperazine-benzoxazole with amide linkage in the 2nd chapter of this thesis. All novel compounds are characterized by antimicrobial activity. In which Compounds **9b** and **9f** shows highest active in both gram positive and gram negative pathogens in antimicrobial activity. All compounds are characterised by TLC, LC-MS, ¹H NMR, ¹³C NMR, IR, Elemental analysis and melting point. Compounds **9b** and **9f**, which shows the highest docking scores of -7.7 kcal/mol and -7.8 kcal/mol respectively. With the exception of compounds **9k** and **9l**, which had molecular weights more than 500, all produced compounds adhered to Lipinski's rule of five. Interestingly, the lipophilicity ratings of all benzoxazole derivatives ranged from 1.94 to 4.31. Using SwissADME, the computational analysis was carried out.

A series of hybrid naphthalene-imidazole derivatives was synthesized in the 3rd chapter of this thesis. All novel compounds are characterized by antimicrobial activity. In which compounds **9k** and **9p** shows highest active in both gram positive and gram negative pathogens in antimicrobial activity. All Compounds are characterised by TLC, LC-MS, ¹H NMR, ¹³C NMR, IR, Elemental analysis and melting point. Also compounds **9k** and **9p** both had significant antibacterial action, achieving the highest docking scores of -8.7 kJ/mol and -8.5 kJ/mol, respectively.

A series of hybrid furan-indoline and pyrrole-indoline derivatives were synthesized in the 4th chapter of this thesis. All compounds are characterized by TLC, LC-MS, ¹H NMR, ¹³C NMR, IR and Elemental analysis. Compound **6k** possesses the greatest binding affinity (-8.4 kcal/mol) in the **6a-k** series. While compound **13e** possesses the greatest binding affinity (-9.8 kcal/mol) in the **13a-k** series. Also these both compounds are more active in gram-positive and gram-negative pathogens.

Bibliography

1. Taylor, A. P., Robinson, R. P., Fobian, Y. M., Blakemore, D. C., Jones, L. H., & Fadeyi, O. Modern advances in heterocyclic chemistry in drug discovery. *Org. Biomol. Chem.*, **2016**, 14(28), 6611–6637. DOI: [10.1039/c6ob00936k](https://doi.org/10.1039/c6ob00936k).
2. Liu, H., Tang, K., Zeng, H., Chen, L., Liang, H., & Jia, Y. Desymmetrization strategy in natural product total synthesis. *Chem. Soc. Rev.*, **2025**. DOI: [10.1039/d5cs00092k](https://doi.org/10.1039/d5cs00092k).
3. Lv, K., Wang, A., Tao, Z., Fu, L., Liu, H., Wang, B., Ma, C., Wang, H., Ma, X., Han, B., Wang, A., Zhang, K., Liu, M., & Lu, Y. hERG optimizations of IMB1603, discovery of alternative benzothiazinones as new antitubercular agents. *Eur. J. Med. Chem.*, **2019**, 179, 208–217. DOI: [10.1016/j.ejmech.2019.06.053](https://doi.org/10.1016/j.ejmech.2019.06.053).
4. Zhuang, W., Wang, Y., Cui, P., Xing, L., Lee, J., Kim, D., Jiang, H., & Oh, Y. Applications of π - π stacking interactions in the design of drug-delivery systems. *J. Control. Release.*, **2018**, 294, 311–326. DOI: [10.1016/j.jconrel.2018.12.014](https://doi.org/10.1016/j.jconrel.2018.12.014).
5. Webling, M., & Schafer, H. J. Cathodic hydrodimerization of nitroolefins. *Beilstein J. Org. Chem.*, **2015**, 11, 1163–1174. DOI: [10.3762/bjoc.11.131](https://doi.org/10.3762/bjoc.11.131).
6. Vitaku, E., Smith, D. T., & Njardarson, J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. *J. Med. Chem.*, **2014**, 57(24), 10257–10274. DOI: [10.1021/jm501100b](https://doi.org/10.1021/jm501100b).
7. Tajti, A., & Sipos, A. Recent advances in the synthesis and biological activity of indole–piperidine hybrids. *Eur. J. Med. Chem.*, **2021**, 213, 113163. DOI: [10.1016/j.ejmech.2020.113163](https://doi.org/10.1016/j.ejmech.2020.113163).
8. Li, S., Li, H., Lian, R., Xie, J., & Feng, R. New perspective of small-molecule antiviral drugs development for RNA viruses. *Virology*, **2024**, 594, 110042. DOI: [10.1016/j.virol.2024.110042](https://doi.org/10.1016/j.virol.2024.110042).
9. Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells. *Cancers*, **2024**, 16(13), 2478–2492. DOI: [10.3390/cancers16132478](https://doi.org/10.3390/cancers16132478).
10. Yan, Y., Xia, X., Fatima, A., Zhang, L., Yuan, G., Lian, F., & Wang, Y. Antibacterial Activity and Mechanisms of Plant Flavonoids against Gram-

- Negative Bacteria Based on the Antibacterial Statistical Model. *Pharmaceuticals*, **2024**, 17(3), 292–310. DOI: [10.3390/ph17030292](https://doi.org/10.3390/ph17030292).
11. Khalaf, S. S., Shalaby, O. A., Hassan, A. R., El-Kherbetawy, M. K., & Mehanna, E. T. Acacia nilotica stem bark extract ameliorates obesity, hyperlipidemia, and insulin resistance in a rat model of high fat diet-induced obesity. *J. Tradit Complement Med.*, **2023**, 13(4), 397–407. DOI: [10.1016/j.jtcme.2023.03.005](https://doi.org/10.1016/j.jtcme.2023.03.005).
 12. Calcaterra, A., Mangiardi, L., Monache, G. D., Quaglio, D., Balducci, S., Berardozi, S., Iazzetti, A., Franzini, R., Botta, B., & Ghirga, F. The Pictet-Spengler reaction updates its habits. *Molecules*, **2020**, 25(2), 414–430. DOI: [10.3390/molecules25020414](https://doi.org/10.3390/molecules25020414).
 13. Roshandel, S. "Catalyst and solvent free microwave-assisted synthesis of substituted 1,2,3-triazoles." *Green Chemistry*, **2018**, 20, 3700–3704. DOI: [10.1039/C8GC01516C](https://doi.org/10.1039/C8GC01516C).
 14. Zhang, M., Chen, Q., & Yang, G. A review on recent developments of indole-containing antiviral agents. *Eur. J. Med. Chem.*, **2014**, 89, 421–441. DOI: [10.1016/j.ejmech.2014.10.065](https://doi.org/10.1016/j.ejmech.2014.10.065).
 15. Akhmadiev, N. S., Mescheryakova, E. S., Akhmetova, V. R., Khairullina, V. R., Khalilov, L. M., & Ibragimov, A. G. Synthesis, crystal structure and docking studies as potential Anti-Inflammatory agents of novel antipyrine sulfanyl derivatives. *J Mol. Struct.*, **2020**, 1228, 129734. DOI: [10.1016/j.molstruc.2020.129734](https://doi.org/10.1016/j.molstruc.2020.129734).
 16. Khan, M., Patujo, J., Mushtaq, I., Ishtiaq, A., Tahir, M. N., Bibi, S., Khan, M. S., Ullah, N., Mustafa, G., Mirza, B., Badshah, A., & Murtaza, I. Anti-diabetic potential, crystal structure, molecular docking, DFT, and optical-electrochemical studies of new dimethyl and diethyl carbamoyl-*N,N'*-disubstituted based thioureas. *J. Mol. Struct.*, **2021**, 1253, 132207. DOI: [10.1016/j.molstruc.2021.132207](https://doi.org/10.1016/j.molstruc.2021.132207).
 17. Abe, A., & Kokuba, H. Harmol induces autophagy and subsequent apoptosis in U251MG human glioma cells through the downregulation of survivin. *Oncology Reports*, **2013**, 29(4), 1333–1342. DOI: [10.3892/or.2013.2242](https://doi.org/10.3892/or.2013.2242).
 18. Scott, L. J., & Perry, C. M. Delavirdine. *Drugs*, **2000**, 60(6), 1411–1444. DOI: [10.2165/00003495-200060060-00013](https://doi.org/10.2165/00003495-200060060-00013).

19. Atadja, P. Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. *Cancer Lett.*, **2009**, 280(2), 233–241. DOI: [10.1016/j.canlet.2009.02.019](https://doi.org/10.1016/j.canlet.2009.02.019).
20. Jida, M., & Ballet, S. An Efficient One-Pot Synthesis of Chiral N-Protected 3-Substituted (Diketo) piperazines via Ugi 4 CR/De-Boc/Cyclization Process. *ChemistrySelect*, **2018**, 3(4), 1027–1031. DOI: [10.1002/slct.201702943](https://doi.org/10.1002/slct.201702943).
21. Kaur, H., Singh, J., & Narasimhan, B. Indole hybridized diazenyl derivatives: synthesis, antimicrobial activity, cytotoxicity evaluation and docking studies. *BMC Chemistry*, **2019**, 13(1). DOI: [10.1186/s13065-019-0580-0](https://doi.org/10.1186/s13065-019-0580-0).
22. Morse, G. D., Reichman, R. C., Fischl, M. A., Para, M., Leedom, J., Powderly, W., Demeter, L. M., Resnick, L., Bassiakos, Y., Timpone, J., Cox, S., & Batts, D. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. *Antiviral Research*, **2000**, 45(1), 47–58. DOI: [10.1016/s0166-3542\(99\)00073-x](https://doi.org/10.1016/s0166-3542(99)00073-x).
23. Srivastava, G., Somasundaram, R. T., Walfish, P. G., & Ralhan, R. Anticancer activity of apaziquone in oral cancer cells and xenograft model: Implications for oral cancer therapy. *PLoS ONE*, **2015**, 10(7), e0133735. DOI: [10.1371/journal.pone.0133735](https://doi.org/10.1371/journal.pone.0133735).
24. Battaglia, S., Boldrini, E., Da Settimo, F., Dondio, G., La Motta, C., Marini, A. M., & Primofiore, G. Indole amide derivatives: synthesis, structure–activity relationships and molecular modelling studies of a new series of histamine H1-receptor antagonists. *Eur J. Med. Chem.*, **1999**, 34(2), 93–105. DOI: [10.1016/s0223-5234\(99\)80044-0](https://doi.org/10.1016/s0223-5234(99)80044-0).
25. Boehringer Ingelheim International. *U.S. patent application US2011/021500 A1*. U.S. Patent and Trademark Office.
26. Amadine, O., Maati, H., Abdelouhadi, K., Fihri, A., Kazzouli, S. E., Len, C., Bouari, A. E., & Solhy, A. Ceria-supported copper nanoparticles: A highly efficient and recyclable catalyst for N-arylation of indole. *J. Mol. Catal. A Chem.*, **2014**, 395, 409–419. DOI: [10.1016/j.molcata.2014.08.009](https://doi.org/10.1016/j.molcata.2014.08.009).
27. Wang, Y., Yuan, Y., Xing, C., & Lu, L. Trifluoromethanesulfonic acid-catalyzed solvent-free bisindolylolation of trifluoromethyl ketones. *Tetrahedron Lett.*, **2014**, 55(5), 1045–1048. DOI: [10.1016/j.tetlet.2013.12.078](https://doi.org/10.1016/j.tetlet.2013.12.078).

28. Liang, K. J., Taylor, O. R., Lopez, A. L., Woo, R. J., & Bahamonde, A. indole nucleophile triggers mechanistic divergence in Ni-Photoredox N-Arylation. *Chem. Eur. J.* **2024**, 524–534. DOI: [10.1002/chem.202402524](https://doi.org/10.1002/chem.202402524).
29. Li, B., Huang, L., Lin, J., Ma, X., Luo, Y., Gai, W., Xie, Y., Zhu, T., Wang, W., & Li, D. Design, synthesis, and biological evaluation of novel penindolone derivatives as potential inhibitors of hemagglutinin-mediated membrane fusion. *Eur. J. Med. Chem.*, **2023**, 258, 115615. DOI: [10.1016/j.ejmech.2023.115615](https://doi.org/10.1016/j.ejmech.2023.115615).
30. Barraza, S. J., Sindac, J. A., Dobry, C. J., Delekta, P. C., Lee, P. H., Miller, D. J., & Larsen, S. D. Synthesis and biological activity of conformationally restricted indole-based inhibitors of neurotropic alphavirus replication: Generation of a three-dimensional pharmacophore. *Bioorg. Med. Chem. Lett.*, **2021**, 46, 128171. DOI: [10.1016/j.bmcl.2021.128171](https://doi.org/10.1016/j.bmcl.2021.128171).
31. Liu, M., Du, H., & Shu, W. Metal-free allylic C–H nitrogenation, oxygenation, and carbonation of alkenes by thianthrenation. *Chemical Science*, **2021**, 13(4), 1003–1022. DOI: [10.1039/d1sc06577g](https://doi.org/10.1039/d1sc06577g).
32. Cao, X., Qiu, D., Zhang, R., Li, Z., & Xu, X. Synthesis, nematocidal evaluation, and SAR study of benzofuran derivatives containing 2-carbonyl thiophene. *Chin. Chem. Lett.*, **2022**, 34(5), 107800. DOI: [10.1016/j.cclet.2022.107800](https://doi.org/10.1016/j.cclet.2022.107800).
33. Leino, T. O., Sieger, P., Yli-Kauhaluoma, J., Wallén, E. A., & Kley, J. T. The azulene scaffold from a medicinal chemist's perspective: Physicochemical and *in vitro* parameters relevant for drug discovery. *Eur. J. Med. Chem.*, **2022**, 237, 114374. DOI: [10.1016/j.ejmech.2022.114374](https://doi.org/10.1016/j.ejmech.2022.114374).
34. Teja, C., & Khan, F. R. N. Tetrabutylammonium-Bromide-Promoted Synthesis of Spirooxindoles through Alkyne-Aldehyde C–C Coupling and 1,3-Dipolar Cycloaddition Using Ytterbium Triflate Catalyst. *ChemistrySelect*, **2020**, 5(21), 6470–6474. DOI: [10.1002/slct.202001335](https://doi.org/10.1002/slct.202001335).
35. Geyer, M., & Vollenweider, F. Serotonin research: contributions to understanding psychoses. *Trends in Pharmacological Sciences*, **2008**, 29(9), 445–453. DOI: [10.1016/j.tips.2008.06.006](https://doi.org/10.1016/j.tips.2008.06.006).
36. Kaur, B. P., Kaur, J., & Chimni, S. S. Arenesulfonyl indole: new precursor for diversification of C-3 functionalized indoles. *RSC Advances*, **2021**, 11(4), 2126–2140. DOI: [10.1039/d0ra09133b](https://doi.org/10.1039/d0ra09133b).
37. Samara, M. T., Cao, H., Helfer, B., Davis, J. M., & Leucht, S. Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and

- meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. *Eur. Neuropsychopharmacol.*, **2014**, 24(7), 1046–1055. DOI: [10.1016/j.euroneuro.2014.03.012](https://doi.org/10.1016/j.euroneuro.2014.03.012).
38. Proskurnina, E. V., Izmailov, D. Y., Sozarukova, M. M., Zhuravleva, T. A., Leneva, I. A., & Poromov, A. A. Antioxidant potential of antiviral drug umifenovir. *Molecules*, **2020**, 25(7), 1577. DOI: [10.3390/molecules25071577](https://doi.org/10.3390/molecules25071577).
39. Wang, J., Pan, X., Rong, Q., Zhao, L., Zhao, L., Dai, W., Zhao, K., & Hu, L. One-pot synthesis of indoles and quinolinones from ortho-tosylaminophenyl-substituted para-quinone methides. *RSC Advances*, **2020**, 10(55), 33455–33460. DOI: [10.1039/d0ra05497f](https://doi.org/10.1039/d0ra05497f).
40. Ghasemi, A., Elfringhoff, A. S., & Lehr, M. Structure–activity relationship studies of 3-dodecanoylindole-2-carboxylic acid inhibitors of cytosolic phospholipase A2 α -mediated arachidonic acid release in intact platelets: variation of the keto moiety. *J. Enzyme Inhib. Med. Chem.*, **2005**, 20(5), 429–437. DOI: [10.1080/14756360500228338](https://doi.org/10.1080/14756360500228338).
41. Mietke, T., Cruchter, T., Larionov, V. A., Faber, T., Harms, K., & Meggers, E. Asymmetric Nazarov cyclizations catalyzed by Chiral-at-Metal complexes. *Adv. Synth. Catal.*, **2018**, 360(11), 2093–2100. DOI: [10.1002/adsc.201701546](https://doi.org/10.1002/adsc.201701546).
42. Ghosh, A. K., & Shahabi, D. Synthesis of amide derivatives for electron deficient amines and functionalized carboxylic acids using EDC and DMAP and a catalytic amount of HOBt as the coupling reagents. *Tetrahedron Lett.*, **2020**, 63, 152719. DOI: [10.1016/j.tetlet.2020.152719](https://doi.org/10.1016/j.tetlet.2020.152719).
43. Han, G., Tamaki, M., & Hruby, V. Fast, efficient and selective deprotection of the tert-butoxycarbonyl (Boc) group using HCl/dioxane (4 m). *J. Pept. Res.*, **2001**, 58(4), 338–341. DOI: [10.1034/j.1399-3011.2001.00935.x](https://doi.org/10.1034/j.1399-3011.2001.00935.x).
44. Patel, H. M., Bari, P., Karpoomath, R., Noolvi, M., Thapliyal, N., Surana, S., & Jain, P. Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening. *RSC Advances*, **2015**, 5(70), 56724–56771. DOI: [10.1039/c5ra05277g](https://doi.org/10.1039/c5ra05277g).
45. Arzine, A., Abchir, O., Chalkha, M., Chebbac, K., Rhazi, Y., Barghady, N., Yamari, I., Moussaoui, A. E., Nakkabi, A., Akhazzane, M., Bakhouch, M., Chtita, S., & Yazidi, M. E. Design, synthesis, In-vitro, In-silico and DFT studies of novel functionalized isoxazoles as antibacterial and antioxidant agents.

- Comput. Biol. Chem.*, **2023**, *108*, 107993. DOI: [10.1016/j.compbiolchem.2023.107993](https://doi.org/10.1016/j.compbiolchem.2023.107993).
46. Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in *Advanced Drug Delivery Reviews* 23 (1997) 3–25. 1. *Adv. Drug Deliv. Rev.*, **2001**, *46*(1–3), 3–26. DOI: [10.1016/s0169-409x\(00\)00129-0](https://doi.org/10.1016/s0169-409x(00)00129-0).
 47. Boyd, M. R., & Paull, K. D. Some practical considerations and applications of the national cancer institute *in vitro* anticancer drug discovery screen. *Drug Dev. Res.*, **1995**, *34*(2), 91–109. DOI: [10.1002/ddr.430340203](https://doi.org/10.1002/ddr.430340203).
 48. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen. *Nat. Rev. Cancer*, **2006**, *6*(10), 813–823. DOI: [10.1038/nrc1951](https://doi.org/10.1038/nrc1951).
 49. Trott, O., & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.*, **2009**, *31*(2), 455–461. DOI: [10.1002/jcc.21334](https://doi.org/10.1002/jcc.21334).
 50. Teraiya, N., Karki, S. S., & Chauhan, A. Synthesis, anticancer evaluation and molecular docking of hexahydroquinoline derivatives as MCL-1 inhibitors and apoptosis inducers. *Anti-Cancer Agents in Medicinal Chemistry*, **2021**, *22*(11), 2142–2155. DOI: [10.2174/1871520621666211021133558](https://doi.org/10.2174/1871520621666211021133558).
 51. Daina, A., Michielin, O., & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.*, **2017**, *7*(1). DOI: [10.1038/srep42717](https://doi.org/10.1038/srep42717).
 52. Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., & Tang, Y. admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. *Bioinform.*, **2018**, *35*(6), 1067–1069. DOI: [10.1093/bioinformatics/bty707](https://doi.org/10.1093/bioinformatics/bty707).
 53. Spessard, G. O. ACD Labs/LogP DB 3.5 and ChemSketch 3.5. *Journal of Chemical Information and Computer Sciences*, **1998**, *38*(6), 1250–1253. DOI: [10.1021/ci980264t](https://doi.org/10.1021/ci980264t).
 54. Abdullahi, A., Yeong, K. Y. Targeting disease with benzoxazoles: a comprehensive review of recent developments. *Med. Chem. Res.*, **2024**, *33*(3), 406–438. DOI: [10.1007/s00044-024-03190-7](https://doi.org/10.1007/s00044-024-03190-7).

55. Li, J. B., Xia, L., Wu, B., Wang, T., Jiang, Z. Z. Design, synthesis and biological estimation of 1-(benzoxazole-2-yl)piperazine and 4-(benzoxazole-2-yl)piperidine derivatives as potential α 1-AR antagonists. *Chin. Chem. Lett.*, **2008**, 19(10), 1193–1195. DOI: [10.1016/j.cclet.2008.06.042](https://doi.org/10.1016/j.cclet.2008.06.042).
56. Elnima, E. I., Zubair, M. U., Al-Badr, A. A. Antibacterial and antifungal activities of benzimidazole and benzoxazole derivatives. *Antimicrob. Agents Chemother.*, **1981**, 19(1), 29–32. DOI: [10.1128/aac.19.1.29](https://doi.org/10.1128/aac.19.1.29).
57. Kaplancikli, Z. A., Turan-Zitouni, G., Revial, G., Guven, K. Synthesis and study of antibacterial and antifungal activities of novel 2 [[(benzoxazole/benzimidazole-2-yl)sulfanyl] acetylamino]thiazoles. *Arch. Pharmacol Res.*, **2004**, 27(11), 1081–1085. DOI: [10.1007/bf02975108](https://doi.org/10.1007/bf02975108).
58. Angajala, G., Subashini, R. Synthesis, molecular modeling, and pharmacological evaluation of new 2-substituted benzoxazole derivatives as potent anti-inflammatory agents. *Struct. Chem.*, **2019**, 31(1), 263–273. DOI: [10.1007/s11224-019-01374-1](https://doi.org/10.1007/s11224-019-01374-1).
59. Osmaniye, D., Celikates, B. K., Saglik, B. N., Levent, S., Cevik, U. A., Cavusoglu, B. K., Ilgin, S., Ozkay, Y., & Kaplancikli, Z. A. Synthesis of some new benzoxazole derivatives and investigation of their anticancer activities. *Eur. J. Med. Chem.*, **2020**, 210, 112979. DOI: [10.1016/j.ejmech.2020.112979](https://doi.org/10.1016/j.ejmech.2020.112979).
60. Patel, D. V., Patel, R. G., Thakor, P. B. Piperidine-containing indole derivatives: recent advances in their synthesis and pharmacological significance. *Bioorg. Chem.*, **2022**, 120, 105615. DOI: [10.1016/j.bioorg.2021.105615](https://doi.org/10.1016/j.bioorg.2021.105615).
61. Tintore, M., Grijalvo, S., Eritja, R., Fabrega, C. Synthesis of oligonucleotides carrying fluorescently labelled O6-alkylguanine for measuring hAGT activity. *Bioorg. Med. Chem. Lett.*, **2015**, 25(22), 5208–5211. DOI: [10.1016/j.bmcl.2015.09.065](https://doi.org/10.1016/j.bmcl.2015.09.065).
62. Kunciewicz, K., Battin, C., Wegrzyn, K., Sieradzan, A., Wardowska, A., Sikorska, E., Giedrojc, I., Smardz, P., Piłkuła, M., Steinberger, P., Rodziewicz-Motowidło, S., & Spodzieja, M. Targeting the HVEM protein using a fragment of glycoprotein D to inhibit formation of the BTLA/HVEM complex. *Bioorg. Chem.*, **2022**, 122, 105748. DOI: [10.1016/j.bioorg.2022.105748](https://doi.org/10.1016/j.bioorg.2022.105748).
63. Ghanem, N. M., Farouk, F., George, R. F., Abbas, S. E., El-Badry, O. M. Design and synthesis of novel imidazo[4,5-*b*]pyridine based compounds as potent

- anticancer agents with CDK9 inhibitory activity. *Bioorg. Chem.*, **2018**, *80*, 565–576. DOI: [10.1016/j.bioorg.2018.07.006](https://doi.org/10.1016/j.bioorg.2018.07.006).
64. Cheng, S., Wang, Y., Zhang, Z., Lv, X., Gao, G. F., Shao, Y., Ma, L., Li, X. Enfuvirtide–PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties. *Eur. J. Med. Chem.*, **2016**, *121*, 232–237. DOI: [10.1016/j.ejmech.2016.05.027](https://doi.org/10.1016/j.ejmech.2016.05.027).
 65. Frieri, M., Kumar, K., Boutin, A. Antibiotic resistance. *J. Infect. Public Health*, **2016**, *10*(4), 369–378. DOI: [10.1016/j.jiph.2016.08.007](https://doi.org/10.1016/j.jiph.2016.08.007).
 66. Brito, A. F., Moreira, L. K. S., Menegatti, R., Costa, E. A. Piperazine derivatives with central pharmacological activity used as therapeutic tools. *Fundam. Clin. Pharmacol.*, **2018**, *33*(1), 13–24. DOI: [10.1111/fcp.12408](https://doi.org/10.1111/fcp.12408).
 67. Arisoy, M.; Temiz-Arpaci, O.; Kaynak-Onurdag, F.; Ozgen, S. Synthesis and Antimicrobial Evaluation of 2-(p-Substituted Phenyl)-5-[(4-substituted piperazin-1-yl) acetamido]benzoxazoles. *Z. Naturforsch. C*, **2014**, *69*(9-10), 368–374. DOI: [10.5560/znc.2014-0024](https://doi.org/10.5560/znc.2014-0024).
 68. Zala, A. R., Kumari, P. Versatile Therapeutic Values of N-Containing Heterocycles Benzimidazole, Piperazine and Piperidine Hybrids. *ChemistrySelect*, **2023**, *8*(37), e202301304. DOI: [10.1002/slct.202301304](https://doi.org/10.1002/slct.202301304).
 69. Mahesh, S., Tang, K.C., Raj, M. Amide bond activation of biological molecules. *Molecules*, **2018**, *23*(10), 2615. DOI: [10.3390/molecules23102615](https://doi.org/10.3390/molecules23102615).
 70. Dorwald, F. Z. *Organic Synthesis on Solid Phase: Supports, Linkers, Reactions*; John Wiley & Sons: Wiley-VCH Verlag GmbH & Co. KGaA, 2002; p 325–368.
 71. Sireesha, R.; Sreenivasulu, R.; Chandrasekhar, C.; Jadav, S. S.; Pavani, Y.; Rao, M. V. B.; Subbarao, M. Design, synthesis, anti-cancer evaluation and binding mode studies of benzimidazole/benzoxazole linked β -carboline derivatives. *J. Mol. Struct.* **2021**, *1226*, 129351. DOI: [10.1016/j.molstruc.2020.129351](https://doi.org/10.1016/j.molstruc.2020.129351).
 72. Zeyrek, C. T.; Erol, M.; Arpacı, O. T.; Arısoy, M.; Salan, A. S. Investigation on four new benzoxazole derivatives: Design, synthesis, ADMET, DFT calculation, antimicrobial activity, and molecular docking. *J. Mol. Struct.* **2025**, *1338*, 142218. DOI: [10.1016/j.molstruc.2025.142218](https://doi.org/10.1016/j.molstruc.2025.142218).
 73. Cuso, G.; Midiri, A.; Gerace, E.; Biondo, C. Bacterial antibiotic resistance: The most critical pathogens. *Pathogens*, **2021**, *10*(10), 1310–1325. DOI: [10.3390/pathogens10101310](https://doi.org/10.3390/pathogens10101310).

74. Huang, L., Zhang, W., Zhang, X., Yin, L., Chen, B., Song, J. Synthesis and pharmacological evaluation of piperidine (piperazine)-substituted benzoxazole derivatives as multi-target antipsychotics. *Bioorg. Med. Chem Lett.* **2015**, 25(22), 5299–5305. DOI: [10.1016/j.bmcl.2015.09.045](https://doi.org/10.1016/j.bmcl.2015.09.045).
75. Di Martino, S., De Rosa, M. The benzoxazole heterocycle: A comprehensive review of the most recent medicinal chemistry developments of antiproliferative, brain-penetrant, and anti-inflammatory agents. *Top. Curr. Chem.*, **2024**, 382(4), 477–490. DOI: [10.1007/s41061-024-00477-6](https://doi.org/10.1007/s41061-024-00477-6).
76. Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., Cheng, Z.. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnol. Adv.*, **2019**, 37(1), 177–192. DOI: [10.1016/j.biotechadv.2018.11.013](https://doi.org/10.1016/j.biotechadv.2018.11.013).
77. Ridolfo, A., Thompkins, L., Bechtol, L., Carmichael, R. Benoxaprofen, a new Anti-Inflammatory agent: Particle-Size effect on dissolution rate and oral absorption in humans. *J. Pharm. Sci.*, **1979**, 68(7), 850–852. DOI: [10.1002/jps.2600680716](https://doi.org/10.1002/jps.2600680716).
78. Kakkar, S., Tahlan, S., Lim, S. M., Ramasamy, K., Mani, V., Shah, S. A. A., Narasimhan, B. Benzoxazole derivatives: design, synthesis and biological evaluation. *Chem. Cent. J.*, **2018**, 12(1), 1–16. DOI: [10.1186/s13065-018-0459-5](https://doi.org/10.1186/s13065-018-0459-5).
79. Zhang, X., Fang, X., Xu, M., Lei, Y., Wu, Z., Hu, X. Enantioselective total synthesis of pseudopteroxazole. *Angew. Chem. Int. Ed.*, **2019**, 58(23), 7845–7849. DOI: [10.1002/anie.201901651](https://doi.org/10.1002/anie.201901651).
80. Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, M., Judge, D. P., Barsdorf, A. I., Huber, P., Patterson, T. A., Riley, S., Schumacher, J., Rapezzi, C. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. *N. Eng. J. Med.*, **2018**, 379(11), 1007–1016. DOI: [10.1056/nejmoa1805689](https://doi.org/10.1056/nejmoa1805689).
81. Barbas, R., Llinas, A., Prohens, R. The solid state landscape of the sildenafil drug. *J. Pharm. Sci.*, **2022**, 111(4), 1104–1109. DOI: [10.1016/j.xphs.2021.08.019](https://doi.org/10.1016/j.xphs.2021.08.019).
82. Brust, T. F., Hayes, M. P., Roman, D. L., Watts, V. J. New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated

- G β γ signaling. *Biochem. Pharmacol.*, **2014**, 93(1), 85–91. DOI: [10.1016/j.bcp.2014.10.014](https://doi.org/10.1016/j.bcp.2014.10.014).
83. Dixon, C. L., Harrison, N. L., Lynch, J. W., Keramidas, A. Zolpidem and eszopiclone prime $\alpha 1\beta 2\gamma 2$ GABAA receptors for longer duration of activity. *Br. J. Pharmacol.*, **2015**, 172(14), 3522–3536. DOI: [10.1111/bph.13142](https://doi.org/10.1111/bph.13142).
 84. Mojzych, M., Karczmarzyk, Z., Wysocki, W., Ceruso, M., Supuran, C. T., Krystof, V., Urbanczyk-Lipkowska, Z., Kalicki, P. New approaches to the synthesis of sildenafil analogues and their enzyme inhibitory activity. *Bioorg. Med. Chem. Lett.*, **2015**, 23(7), 1421–1429. DOI: [10.1016/j.bmc.2015.02.026](https://doi.org/10.1016/j.bmc.2015.02.026).
 85. Su, C., Lin, S., Wang, H., Hsu, F., Chung, J. G., Hsu, L. The inhibitory effect and mechanism of quetiapine on tumor progression in hepatocellular carcinoma in vivo. *Environmental Toxicology*, **2021**, 37(1), 92–100. DOI: [10.1002/tox.23380](https://doi.org/10.1002/tox.23380).
 86. Huynh, T. N. T., Tankam, T., Koguchi, S., Rerkrachaneekorn, T., Sukwattanasinitt, M., Wacharasindhu, S. Electrochemical NaI/NaCl-mediated one-pot synthesis of 2-aminobenzoxazoles in aqueous media via tandem addition–cyclization. *Green Chem.*, **2021**, 23(14), 5189–5194. DOI: [10.1039/d1gc01131f](https://doi.org/10.1039/d1gc01131f).
 87. Baxter, C. A., Cleator, E., Brands, K. M. J., Edwards, J. S., Reamer, R. A., Sheen, F. J., Stewart, G. W., Strotman, N. A., Wallace, D. J. The first Large-Scale synthesis of MK-4305: a dual orexin receptor antagonist for the treatment of sleep disorder. *Org. Process Res. Dev.*, **2011**, 15(2), 367–375. DOI: [10.1021/op1002853](https://doi.org/10.1021/op1002853).
 88. Li, K., Liu, Y., Lin, X., Yang, G. Copper-Containing Polyoxometalate-Based Metal–Organic frameworks as heterogeneous catalysts for the synthesis of N-Heterocycles. *Inorg. Chem.*, **2022**, 61(18), 6934–6942. DOI: [10.1021/acs.inorgchem.2c00287](https://doi.org/10.1021/acs.inorgchem.2c00287).
 89. Nesaragi, A. R., Kamble, R. R., Dixit, S., Kodasi, B., Hoolageri, S. R., Bayannavar, P. K., Dasappa, J. P., Vootla, S., Joshi, S. D., Kumbar, V. M. Green synthesis of therapeutically active 1,3,4-oxadiazoles as antioxidants, selective COX-2 inhibitors and their *in silico* studies. *Bioorg. Med. Chem. Lett.*, **2021**, 43, 128112. DOI: [10.1016/j.bmcl.2021.128112](https://doi.org/10.1016/j.bmcl.2021.128112).

90. Wu, J., Wu, F., Li, Z., Fang, M., Liu, Y., Liu, Y. Efficient Monofluoroalkylation of Thiophenols or Phenols with α -Bromo- α -Fluoroketones under Mild Conditions. *Synthesis*, **2021**, 53(13), 2293–2303. DOI: [10.1055/a-1395-4788](https://doi.org/10.1055/a-1395-4788).
91. Li, D., Liu, C., Jiang, X., Lin, Y., Zhang, J., Li, Y., You, X., Jiang, W., Chen, M., Xu, Y., Si, S. Design, synthesis, and evaluation of substituted 2-acylamide-1,3-benzo[d]zole analogues as agents against MDR- and XDR-MTB. *Eur. J. Med. Chem.*, **2020**, 209, 112898. DOI: [10.1016/j.ejmech.2020.112898](https://doi.org/10.1016/j.ejmech.2020.112898).
92. Sahoo, S. K., Maddipatla, S., Gajula, S. N. R., Ahmad, M. N., Kaul, G., Nanduri, S., Sonti, R., Dasgupta, A., Chopra, S., Yaddanapudi, V. M. Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug-resistant Mycobacterium tuberculosis, demonstrating bactericidal efficacy. *Bioorg. Med. Chem.*, **2022**, 64, 116777. DOI: [10.1016/j.bmc.2022.116777](https://doi.org/10.1016/j.bmc.2022.116777).
93. Chiappini, S., Schifano, F. Is there a potential of misuse for quetiapine. Literature review and analysis of the European Medicines Agency adverse drug reactions' database. *J. Clin. Psychopharmacol.*, **2018**, 38(1), 72–79. DOI: [10.1097/jcp.0000000000000814](https://doi.org/10.1097/jcp.0000000000000814).
94. Chahal, S., Rani, P., Kiran, Sindhu, J., Joshi, G., Ganesan, A., Kalyaanamoorthy, S., Mayank, Kumar, P., Singh, R., Negi, A. Design and development of COX-II inhibitors: Current scenario and future perspective. *ACS Omega*, **2023**, 8(20), 17446–17498. DOI: [10.1021/acsomega.3c00692](https://doi.org/10.1021/acsomega.3c00692).
95. Abdullahi, A., Yeong, K. Y. Targeting disease with benzoxazoles: comprehensive review of recent developments. *Med. Chem. Res.*, **2024**, 33(3), 406-438. DOI: [10.1007/s00044-024-03190-7](https://doi.org/10.1007/s00044-024-03190-7).
96. Escudero-Martínez JM, Perez-Pertejo Y, Reguera RM, Castro Ma, Rojo MV, Santiago C, et al. Antileishmanial activity and tubulin polymerization inhibition of podophyllotoxin derivatives on Leishmania infantum. *Int J Parasitol Drugs Drug Resist.* **2017**, 7, 272–285. DOI: [10.1016/j.ijpddr.2017.06.003](https://doi.org/10.1016/j.ijpddr.2017.06.003).
97. Gabr MT, MacHalz D, Pach S, Wolber G. A benzoxazole derivative as an inhibitor of anaerobic choline metabolism by human gut microbiota. *RSC Med Chem.* **2020**, 11, 1402–1412. DOI: [10.1039/D0MD00218F](https://doi.org/10.1039/D0MD00218F).
98. Tariq S, Kamboj P, Alam O, Amir M. 1,2,4-Triazole-based benzothiazole/benzoxazole derivatives: Design, synthesis, p38 α MAP kinase

- inhibition, anti-inflammatory activity and molecular docking studies. *Bioorg Chem.* **2018**, *8*, 1630–1641. DOI: [10.1016/j.bioorg.2018.09.015](https://doi.org/10.1016/j.bioorg.2018.09.015).
99. Wu, Q., Liang, J., Lin, S., Zhou, X., Bai, L., Deng, Z., Wang, Z. Characterization of the Biosynthesis Gene Cluster for the Pyrrole Polyether Antibiotic Calcimycin (A23187) in *Streptomyces chartreusis* NRRL 3882. *Antimicrob. Agents Chemother.*, **2010**, *55*(3), 974–982. DOI: [10.1128/aac.01130-10](https://doi.org/10.1128/aac.01130-10).
 100. Li, X. W., Tao, L., Li, Y. T., Wu, Z. Y., Yan, C. W. Bimetallic complexes constructed from asymmetrical *N,N'*-bis(substituted)-oxamide: Cytotoxicities, and reactivities towards DNA and protein. *Eur. J. Med. Chem.*, **2012**, *54*, 697–708. DOI: [10.1016/j.ejmech.2012.06.022](https://doi.org/10.1016/j.ejmech.2012.06.022).
 101. Kuzu, B., Sari, O., Erdem, S. S., Algul, O., Menges, N. Synthesis of benzoxazole-2-carboxylate derivatives: electronic and position-effect of functional groups and computational modeling of the selectivity for Oxazole ring. *ChemistrySelect*, **2021**, *6*(10), 2529–2538. DOI: [10.1002/slct.202100174](https://doi.org/10.1002/slct.202100174).
 102. Hattori, T., Yamamoto, H. Trimethylaluminum-mediated one-pot peptide elongation. *Chem. Sci.*, **2023**, *14*(21), 5795–5801. DOI: [10.1039/d3sc00208j](https://doi.org/10.1039/d3sc00208j).
 103. Al-Lolage, F. A., Bartlett, P. N., Gounel, S., Staigre, P., Mano, N. Site-Directed immobilization of bilirubin oxidase for electrocatalytic oxygen reduction. *ACS Catal.*, **2019**, *9*(3), 2068–2078. DOI: [10.1021/acscatal.8b04340](https://doi.org/10.1021/acscatal.8b04340).
 104. Han, S., Kim, Y. Recent development of peptide coupling reagents in organic synthesis. *Tetrahedron*, **2004**, *60*(11), 2447–2467. DOI: [10.1016/j.tet.2004.01.020](https://doi.org/10.1016/j.tet.2004.01.020).
 105. Jorgensen J. H., Swenson J. M., Tenover F. C., Ferraro M. J., Hindler J. A., Murray P. R. Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of *Streptococcus pneumoniae*. *J. Clin. Microbiol.*, **1994**, *32*(10), 2448–2459. DOI: [10.1128/jcm.32.10.2448-2459.1994](https://doi.org/10.1128/jcm.32.10.2448-2459.1994).
 106. Juneja, T., Chakraborty, J., Kapadiya, K., Kamdar, J. H. Identification of Phytochemical Inhibitors Targeting VEGFA and TGFBR2 of Cervical Cancer: Insights from Virtual Screening, ADMET and DFT Studies. *ChemistrySelect*, **2024**, *9*(17). DOI: [10.1002/slct.202304901](https://doi.org/10.1002/slct.202304901).
 107. Shah, A., Teraiya, N., Kamdar, J. H., Juneja, T., Sangani, C. B., Ahmed, S., Kapadiya, K. Novel purine derivatives as selective CDK2 inhibitors with

- potential anticancer activities: Design, synthesis and biological evaluation. *Bioorg. Chem.*, **2024**, *153*(1), 107841. DOI: [10.1016/j.bioorg.2024.107841](https://doi.org/10.1016/j.bioorg.2024.107841).
108. Mandir, D. P., Mandir, S. D., Kamdar, J. H., Tala, S. D. Synthesis, anti-microbial evaluation, and *in silico* studies of novel quinoline-isoxazole hybrids *Synth. Commun.*, **2024**, *54*(18), 1603–1619. DOI: [10.1080/00397911.2024.2397813](https://doi.org/10.1080/00397911.2024.2397813).
 109. Bakchi, B., Krishna, A. D., Sreecharan, E., Ganesh, V. B. J., Niharika, M., Maharshi, S., Puttagunta, S. B., Sigalapalli, D. K., Bhandare, R. R., Shaik, A. B. An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist's perspective. *J. Mol. Struct.*, **2022**, *1259*, 132712. DOI: [10.1016/j.molstruc.2022.132712](https://doi.org/10.1016/j.molstruc.2022.132712).
 110. Jatiya, J. N., Patel, A. S., Savant, M. M. Synthesis, *in vitro* antimicrobial evaluation, ADMET properties, and molecular docking studies of novel thiazole derivatives. *Russ. J. Gen. Chem.*, **2023**, *93*(10), 2621–2631. DOI: [10.1134/s107036322310016x](https://doi.org/10.1134/s107036322310016x).
 111. Kunin, C. M., Ellis, W. Y. Antimicrobial activities of mefloquine and a series of related compounds. *Antimicrob. Agents Chemother.*, **2000**, *44*(4), 848–852. DOI: [10.1128/aac.44.4.848-852.2000](https://doi.org/10.1128/aac.44.4.848-852.2000).
 112. Modasiya, J. B., Kamdar, J. H., Kapadiya, K. M., Gundaraniya, S., George, J. J. A computational approach to finding novel drug targets and their natural product inhibitors for *Aspergillus flavus*. In *Nanotechnology and In Silico Tools*, Elsevier. **2024**, 219–231. DOI: [10.1016/B978-0-443-15457-7.00020-4](https://doi.org/10.1016/B978-0-443-15457-7.00020-4).
 113. Ferreira, L. G., Dos Santos, R. N., Oliva, G.; Andricopulo, A. D. Molecular docking and structure-based drug design strategies. *Molecules*, **2015**, *20*(7), 13384–13421. DOI: [10.3390/molecules200713384](https://doi.org/10.3390/molecules200713384).
 114. Adasme, M. F., Linnemann, K. L., Bolz, S. N., Kaiser, F., Salentin, S., Haupt, V. J., Schroeder, M. PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA. *Nucleic Acids Research*, **2021**, *49*(W1), W530–W534. DOI: [10.1093/nar/gkab294](https://doi.org/10.1093/nar/gkab294).
 115. Childers, M. C.; Daggett, V. Insights from Molecular Dynamics Simulations for Computational Protein Design. *Mol. Syst. Des. Eng.* **2017**, *2*, 9–33. DOI: [10.1039/C6ME00083E](https://doi.org/10.1039/C6ME00083E).

116. Daina, A., Michielin, O., Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules *Sci. Rep.*, **2017**, 7(1). DOI: [10.1038/srep42717](https://doi.org/10.1038/srep42717).
117. Manthey, J., Guthrie, N., & Grohmann, K. Biological properties of citrus flavonoids pertaining to cancer and inflammation. *Curr. Med. Chem.*, **2001**, 8(2), 135–153. DOI: [10.2174/0929867013373723](https://doi.org/10.2174/0929867013373723).
118. Deng, H., Lei, Q., Wu, Y., He, Y., & Li, W. Activity-based protein profiling: Recent advances in medicinal chemistry. *Eur. J. Med. Chem.*, **2020**, 191, 112151. DOI: [10.1016/j.ejmech.2020.112151](https://doi.org/10.1016/j.ejmech.2020.112151).
119. Lin, X., Xiang, H., & Luo, G. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance. *Eur. J. Med. Chem.*, **2020**, 206, 112689. DOI: [10.1016/j.ejmech.2020.112689](https://doi.org/10.1016/j.ejmech.2020.112689).
120. Borgers, M. Mechanism of Action of Antifungal Drugs, with Special Reference to the Imidazole Derivatives. *Clin. Infect. Dis.*, **1980**, 2(4), 520–534. DOI: [10.1093/clinids/2.4.520](https://doi.org/10.1093/clinids/2.4.520).
121. Navarrete-Vázquez, G., Hidalgo-Figueroa, S., Torres-Piedra, M., Vergara-Galicia, J., Rivera-Leyva, J. C., Estrada-Soto, S., León-Rivera, I., Aguilar-Guardarrama, B., Rios-Gómez, Y., & Villalobos-Molina, R. Synthesis, vasorelaxant activity and antihypertensive effect of benzo[d]imidazole derivatives. *Bioorg. Med. Chem.*, **2010**, 18(11), 3985–3991. DOI: [10.1016/j.bmc.2010.04.027](https://doi.org/10.1016/j.bmc.2010.04.027).
122. Nascimento, M. V. P. S., Munhoz, A. C. M., Theindl, L. C., Mohr, E. T. B., Saleh, N., Parisotto, E. B., Rossa, T. A., Zamoner, A., Creczynski-Pasa, T. B., Filippin-Monteiro, F. B., Sá, M. M., & Dalmarco, E. M. A novel tetrasubstituted imidazole as a prototype for the development of anti-inflammatory drugs. *Inflammation*, **2018**, 41(4), 1334–1348. DOI: [10.1007/s10753-018-0782-y](https://doi.org/10.1007/s10753-018-0782-y).
123. Teli, G., & Chawla, P. A. Hybridization of Imidazole with Various Heterocycles in Targeting Cancer: A Decade's Work. *ChemistrySelect*, **2021**, 6(19), 4803–4836. DOI: [10.1002/slct.202101038](https://doi.org/10.1002/slct.202101038).
124. De Araujo, J. S., Garcia-Rubia, A., Sebastian-Perez, V., Kalejaiye, T. D., Da Silva, P. B., Fonseca-Berzal, C. R., Maes, L., De Koning, H. P., De Nazare Correia Soeiro, M., & Gil, C. Imidazole derivatives as promising agents for the treatment of Chagas disease. *Antimicrob. Agents Chemo.*, **2019**, 63(4). DOI: [10.1128/aac.02156-18](https://doi.org/10.1128/aac.02156-18).

125. Wang, Y., Qin, Y., Yang, N., Zhang, Y., Liu, C., & Zhu, H. Synthesis, biological evaluation, and molecular docking studies of novel 1-benzene acyl-2-(1-methylindol-3-yl)-benzimidazole derivatives as potential tubulin polymerization inhibitors. *Eur. J. Chemistry*, **2015**, 99, 125-137. DOI: [10.1016/j.ejmech.2015.05.021](https://doi.org/10.1016/j.ejmech.2015.05.021).
126. Laxman, K., Kumar, A., & Ravikanth, M. Polycyclic Aromatic Hydrocarbon-/Heterocycle-Embedded porphyrinoids. *Asian J. Org. Chem.*, **2020**, 9(2), 162–180. DOI: [10.1002/ajoc.201900752](https://doi.org/10.1002/ajoc.201900752).
127. Tandon, R., Luxami, V., Kaur, H., Tandon, N., & Paul, K. 1,8-Naphthalimide: a potent DNA intercalator and target for cancer therapy. *Chem. Rec.*, **2017**, 17(10), 956–993. DOI: [10.1002/tcr.201600134](https://doi.org/10.1002/tcr.201600134).
128. Lee, H., Jeon, Y., Moon, H., Lee, E. H., Lee, T. H., & Kim, H. Synthesis of 1,4-Dialkoxynaphthalene-Based imidazolium salts and their cytotoxicity in cancer cell lines. *Int. J. Mol. Sci.*, **2023**, 24(3), 2713. DOI: [10.3390/ijms24032713](https://doi.org/10.3390/ijms24032713).
129. El-Wakil, M. H., Ashour, H. M., Saudi, M. N., Hassan, A. M., & Labouta, I. M. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors. *Bioorg. Chem.*, **2017**, 73, 154–169. DOI: [10.1016/j.bioorg.2017.06.009](https://doi.org/10.1016/j.bioorg.2017.06.009).
130. Sawyer, P. R., Brogden, R. N., Pinder, R. M., Speight, T. M., & Avery, G. S. Clotrimazole. *Drugs*, **1975**, 9(6), 424-447. DOI: [10.2165/00003495-197509060-00003](https://doi.org/10.2165/00003495-197509060-00003).
131. Belelli, D., Lambert, J. J., Peters, J. A., Wafford, K., & Whiting, P. J. The interaction of the general anesthetic etomidate with the γ -aminobutyric acid type A receptor is influenced by a single amino acid. *Proce. Nation. Academy Sci.*, **1997**, 94(20), 11031–11036. DOI: [10.1073/pnas.94.20.11031](https://doi.org/10.1073/pnas.94.20.11031).
132. Mazzon, M., Ortega-Prieto, A. M., Imrie, D., Luft, C., Hess, L., Czieso, S., Grove, J., Skelton, J. K., Farleigh, L., Bugert, J. J., Wright, E., Temperton, N., Angell, R., Oxenford, S., Jacobs, M., Ketteler, R., Dorner, M., & Marsh, M. Identification of Broad-Spectrum antiviral compounds by targeting viral entry. *Viruses*, **2019**, 11(2), 176. DOI: [10.3390/v11020176](https://doi.org/10.3390/v11020176).
133. Singh, N., White, S., Kalagara, S., & Kadavakollu, S. Inhibition of CYP2S1 mediated metabolism of anticancer prodrug AQ4N by liarozole. *J. Appl. Pharm. Sci.*, **2017**. DOI: [10.7324/japs.2017.70201](https://doi.org/10.7324/japs.2017.70201).

134. Brito, C. L., Lins, R. S., Bertotti, M., Ferreira, E. I., & La-Scalea, M. A. Free radical formation evidence from Nimorazole electrochemical reduction in aqueous media. *Electrochim. Acta*, **2021**, *403*, 139709. DOI: [10.1016/j.electacta.2021.139709](https://doi.org/10.1016/j.electacta.2021.139709).
135. Pierard, G. E., Hermanns-Le, T., Delvenne, P., & Pierard-Franchimont, C. Miconazole, a pharmacological barrier to skin fungal infections. *Expert Opin. Pharmacother.*, **2012**, *13*(8), 1187–1194. DOI: [10.1517/14656566.2012.687047](https://doi.org/10.1517/14656566.2012.687047).
136. Acar, M. F., Sari, S., & Dalkara, S. Synthesis, in vivo anticonvulsant testing, and molecular modeling studies of new nafimidone derivatives. *Drug Development Research*, **2019**, *80*(5), 606–616. DOI: [10.1002/ddr.21538](https://doi.org/10.1002/ddr.21538).
137. Abozeid, M. A., El-Sawi, A. A., Abdelmoteleb, M., Awad, H., Abdel-Aziz, M. M., Abdel-Rahman, A. H., & El-Desoky, E. I. Synthesis of novel naphthalene-heterocycle hybrids with potent antitumor, anti-inflammatory and antituberculosis activities. *RSC Advances*, **2020**, *10*(70), 42998–43009. DOI: [10.1039/d0ra08526j](https://doi.org/10.1039/d0ra08526j).
138. Liu, L. Z., Ma, T., Zhou, J., Hu, Z. L., Zhang, X. J., Zhang, H. Z., Zeng, M., Liu, J., Li, L., Jiang, Y., Zou, Z., Wang, F., Zhang, L., Xu, J., Wang, J., Xiao, F., Fang, X., Zou, H., Efanov, A. M., Chen, J. Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human. *Bioorg. Med. Chem. Lett.*, **2019**, *30*(5), 126857. DOI: [10.1016/j.bmcl.2019.126857](https://doi.org/10.1016/j.bmcl.2019.126857).
139. Buffa, V., Meyners, C., Sugiarto, W. O., Bauder, M., Gaali, S., & Hausch, F. 1,4-Pyrazolyl-Containing SAFit-Analogues are Selective FKBP51 Inhibitors With Improved Ligand Efficiency and Drug-Like Profile. *Chem. Med. Chem.*, **2024**, *19*(17). DOI: [10.1002/cmdc.202400264](https://doi.org/10.1002/cmdc.202400264).
140. Sasaki, K., Takada, H., Hayashi, C., Ohya, K., Yamaguchi, Y., Takahashi, Y., Igarashi, M., & Shibasaki, M. Synthesis of novobiocin derivatives and evaluation of their antigonococcal activity and pharmacokinetics. *Bioorg. Med. Chem.*, **2023**, *92*, 117381. DOI: [10.1016/j.bmc.2023.117381](https://doi.org/10.1016/j.bmc.2023.117381).
141. Xi, Q., Wang, M., Jia, W., Yang, M., Hu, J., Jin, J., Chen, X., Yin, D., & Wang, X. Design, synthesis, and biological evaluation of amidobenzimidazole derivatives as stimulator of interferon genes (STING) receptor agonists. *J. Med. Chem.*, **2019**, *63*(1), 260–282. DOI: [10.1021/acs.jmedchem.9b01567](https://doi.org/10.1021/acs.jmedchem.9b01567).

142. Fan, S., Wu, W., Su, Y., Han, X., Wang, Z., & Zhu, J. Co(III)-Catalyzed Coupling of Enaminones with Oxadiazolones for Imidazole Synthesis. *Org. Lett.*, **2024**, DOI: [10.1021/acs.orglett.4c02736](https://doi.org/10.1021/acs.orglett.4c02736).
143. Peng, X., Li, L., Chen, J., Ren, Y., Liu, J., Yu, Z., Cao, H., & Chen, J. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma. *J. Med. Chem.*, **2022**, 65(3), 2434–2457. DOI: [10.1021/acs.jmedchem.1c01863](https://doi.org/10.1021/acs.jmedchem.1c01863).
144. Sharma, D., Narasimhan, B., Kumar, P., Judge, V., Narang, R., De Clercq, E., & Balzarini, J. Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. *Eur. J. Med. Chem.*, **2008**, 44(6), 2347–2353. DOI: [10.1016/j.ejmech.2008.08.010](https://doi.org/10.1016/j.ejmech.2008.08.010).
145. Nascimento, M. V. P. S., Munhoz, A. C. M., Theindl, L. C., Mohr, E. T. B., Saleh, N., Parisotto, E. B., Rossa, T. A., Zamonier, A., Creczynski-Pasa, T. B., Filippin-Monteiro, F. B., Sá, M. M., & Dalmarco, E. M. A novel tetrasubstituted imidazole as a prototype for the development of anti-inflammatory drugs. *Inflammation*, **2018**, 41(4), 1334–1348. DOI: [10.1007/s10753-018-0782-y](https://doi.org/10.1007/s10753-018-0782-y).
146. Vitale, R. M., Rispoli, V., Desiderio, D., Sgammato, R., Thellung, S., Canale, C., Vassalli, M., Carbone, M., Ciavatta, M. L., Mollo, E., Felicità, V., Arcone, R., Capoggiani, M. G., Masullo, M., Florio, T., & Amodeo, P. In Silico Identification and Experimental Validation of Novel Anti-Alzheimer's Multitargeted Ligands from a Marine Source Featuring a 2-Aminoimidazole plus Aromatic Group Scaffold. *ACS Chem. Neu.*, **2018**, 9(6), 1290–1303. DOI: [10.1021/acschemneuro.7b00416](https://doi.org/10.1021/acschemneuro.7b00416).
147. Amir, M., Ali, I., & Hassan, M. Z. Imidazole incorporated semicarbazone derivatives as a new class of anticonvulsants: design, synthesis and *In-Vivo* screening. *Med. Chem.*, **2013**, 9(4), 571–580. DOI: [10.2174/1573406411309040011](https://doi.org/10.2174/1573406411309040011).
148. Malik, M. S., Alsantali, R. I., Jamal, Q. M. S., Seddigi, Z. S., Morad, M., Alsharif, M. A., Hussein, E. M., Jassas, R. S., Al-Rooqi, M. M., Abduljaleel, Z., Babalghith, A. O., Altass, H. M., Moussa, Z., & Ahmed, S. A. New Imidazole-Based N-Phenylbenzamide derivatives as potential anticancer Agents: Key computational Insights. *Front. Chem.*, **2022**, 9. DOI: [10.3389/fchem.2021.808556](https://doi.org/10.3389/fchem.2021.808556).

149. Mullaivendhan, J., Akbar, I., Gatasheh, M. K., Hatamleh, A. A., Ahamed, A., Abuthakir, M. H. S., & Gurusamy, R. Cu (II)-catalyzed: synthesis of imidazole derivatives and evaluating their larvicidal, antimicrobial activities with DFT and molecular docking studies. *BMC Chem.*, **2023**, 17(1). DOI: [10.1186/s13065-023-01067-1](https://doi.org/10.1186/s13065-023-01067-1).
150. Campos, J. F., & Berteina-Raboin, S. Tandem Catalysis: Synthesis of Nitrogen-Containing Heterocycles. *Catalysts*, **2020**, 10(6), 631. DOI: [10.3390/catal10060631](https://doi.org/10.3390/catal10060631).
151. Behrouz, S., Rad, M. N. S., Abdollahzadeh, M., & Piltan, M. A. Ultrasound-Promoted mild, and efficient protocol for Three-Component synthesis of 2,4,5-Trisubstituted imidazoles using urea and PPH₃ as the sources of nitrogen and organocatalyst. *ChemistrySelect*, **2020**, 5(25), 7467–7473. DOI: [10.1002/slct.202001722](https://doi.org/10.1002/slct.202001722).
152. Zuev, D., Vrudhula, V. M., Michne, J. A., Dasgupta, B., Pin, S. S., Huang, X. S., Wu, D., Gao, Q., Zhang, J., Taber, M. T., Macor, J. E., & Dubowchik, G. M. Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7*H*-imidazo[1,2-*a*]imidazol-3-ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists. *Bioorg. Med. Chem. Lett.*, **2010**, 20(12), 3669–3674. DOI: [10.1016/j.bmcl.2010.04.094](https://doi.org/10.1016/j.bmcl.2010.04.094).
153. Zhang, K., Chen, Y., Song, L., & Cai, L. Progress of catalytic Mitsunobu reaction in the two decades. *Asian J. Org. Chem.*, **2023**, 12(2). DOI: [10.1002/ajoc.202200707](https://doi.org/10.1002/ajoc.202200707).
154. Fihri, A., Bouhrara, M., Nekoueishahraki, B., Basset, J., & Polshettiwar, V. Nanocatalysts for Suzuki cross-coupling reactions. *Chem. Soc. Rev.*, **2011**, 40(10), 5181. DOI: [10.1039/c1cs15079k](https://doi.org/10.1039/c1cs15079k).
155. Yeerong, K., Chantawannakul, P., Anuchapreeda, S., Wangtueai, S., & Chaiana, W. Optimization of Hydrolysis Conditions, Isolation, and Identification of Biologically Active Peptides Derived from *Acheta domesticus* for Antioxidant and Collagenase Inhibition. *Antioxidants*, **2024**, 13(3), 367–380. DOI: [10.3390/antiox13030367](https://doi.org/10.3390/antiox13030367)
156. Jorgensen, J. H., & Turnidge, J. D. Susceptibility test methods: Dilution and disk diffusion methods. *Manual Clinic. Microbiol.*, **2015**, 1253–1173. DOI: [10.1128/9781555817381.ch71](https://doi.org/10.1128/9781555817381.ch71).

157. Hossain, T. J. Methods for screening and evaluation of antimicrobial activity: A review of protocols, advantages, and limitations. *Eur. J. Microbiol. Immunol.*, **2024**, *14*(2), 97–115. DOI: [10.1556/1886.2024.00035](https://doi.org/10.1556/1886.2024.00035).
158. Juneja, T., Chakraborty, J., Kapadiya, K., & Kamdar, J. H. Identification of Phytochemical Inhibitors Targeting VEGFA and TGFBR2 of Cervical Cancer: Insights from Virtual Screening, ADMET and DFT Studies. *ChemistrySelect*, **2024**, *9*(17), e202304901. DOI: [10.1002/slct.202304901](https://doi.org/10.1002/slct.202304901)
159. Mandir, D. P., Mandir, S. D., Kamdar, J. H., & Tala, S. D. Synthesis, antimicrobial evaluation, and *in silico* studies of novel quinoline-isoxazole hybrids. *Synth. Commun.*, **2024**, *54*(18), 1603–1619. DOI: [10.1080/00397911.2024.2397813](https://doi.org/10.1080/00397911.2024.2397813).
160. Modasiya, J. B., Kamdar, J. H., Kapadiya, K. M., Gundaraniya, S., & George, J. J. A computational approach to finding novel drug targets and their natural product inhibitors for *Aspergillus flavus*. *Nanotechnology and In Silico Tools*, Elsevier. **2024**, 219–231. DOI: [10.1016/B978-0-443-15457-7.00020-4](https://doi.org/10.1016/B978-0-443-15457-7.00020-4).
161. Ferreira, L.G., Dos Santos, R.N., Oliva, G. and Andricopulo, A.D., Molecular docking and structure-based drug design strategies. *Molecules*, **2015**, *20*(7), 13384–13421. DOI: [10.3390/molecules200713384](https://doi.org/10.3390/molecules200713384).
162. Childers, M. C.; Daggett, V. Insights from Molecular Dynamics Simulations for Computational Protein Design. *Mol. Syst. Des. Eng.* **2017**, *2*, 9–33. DOI: [10.1039/C6ME00083E](https://doi.org/10.1039/C6ME00083E).
163. Shah, A., Teraiya, N., Kamdar, J. H., Juneja, T., Sangani, C. B., Ahmed, S., & Kapadiya, K. Novel purine derivatives as selective CDK2 inhibitors with potential anticancer activities: Design, synthesis and biological evaluation. *Bioorg. Chem.*, **2024**, *153*, 10784. DOI: [10.1016/j.bioorg.2024.107841](https://doi.org/10.1016/j.bioorg.2024.107841).
164. Bar-On, Y. M., Phillips, R., & Milo, R. The biomass distribution on Earth. *Proceedings of the National Academy of Sciences*, **2018**, *115*(25), 6506–6511. DOI: [10.1073/pnas.1711842115](https://doi.org/10.1073/pnas.1711842115).
165. Ikuta, K. S.; Swetschinski, L. R.; Aguilar, G. R.; Sharara F.; Mestrovic T.; Gray, A. P.; Weaver, N. D.; Wool, E. E.; Han, C.; Hayoon, A. G.; et. al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet*, **2022**, *400*, 2221–2248. DOI: [10.1016/S0140-6736\(22\)02185-7](https://doi.org/10.1016/S0140-6736(22)02185-7).

166. Prestinaci, F., Pezzotti, P., & Pantosti, A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog. Glob. Health.*, **2015**, 109(7), 309–318. DOI: [10.1179/2047773215y.00000000030](https://doi.org/10.1179/2047773215y.00000000030)
167. Khloya, P., Celik, G., SitaRam, Vullo, D., Supuran, C. T., & Sharma, P. K. 4-Functionalized 1,3-diarylpurazoles bearing benzenesulfonamide moiety as selective potent inhibitors of the tumor associated carbonic anhydrase isoforms IX and XII. *Eur. J. Med. Chem.*, **2014**, 76, 284–290. DOI: [10.1016/j.ejmech.2014.02.023](https://doi.org/10.1016/j.ejmech.2014.02.023).
168. Zhu, J., Yang, L., Liu, H., Sun, S., Li, J., Zhang, L., Sun, H., Cheng, M., Lin, B., & Liu, Y. Syntheses of tetracyclic indoline derivatives via Gold(I)-Catalyzed Hydroamination/Cycloisomerization cascade of 2-Ethynyltryptamides. *J. Org. Chem.*, **2024**, 89(5), 3331–3344. DOI: [10.1021/acs.joc.3c02784](https://doi.org/10.1021/acs.joc.3c02784).
169. He, X., Liu, K., Yan, S., Wang, Y., Jiang, Y., Zhang, X., & Fan, X. Synthesis of 1,7-Fused Indolines Tethered with Spiroindolinone Based on C–H Activation Strategy with Air as a Sustainable Oxidant. *J. Org. Chem.*, **2024**, 89(3), 1880–1897. DOI: [10.1021/acs.joc.3c02630](https://doi.org/10.1021/acs.joc.3c02630).
170. Vinod, A., Mouli, H. M. C., Pal, P., Myrsing, E., Naik, V. Y., Ghosh, H., & Jana, A. Sustainable synthesis of Indole-Substituted densely functionalized pyrrole. *J. Org. Chem.*, **2024**, 89(3), 1407–1416. DOI: [10.1021/acs.joc.3c01871](https://doi.org/10.1021/acs.joc.3c01871).
171. Vitaku, E., Smith, D. T., & Njardarson, J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals. *J. Med. Chem.*, **2014**, 57(24), 10257–10274. DOI: [10.1021/jm501100b](https://doi.org/10.1021/jm501100b).
172. Valeur, E., & Bradley, M. Amide bond formation: beyond the myth of coupling reagents. *Chem. Soc. Rev.*, **2008**, 38(2), 606–631. DOI: [10.1039/b701677h](https://doi.org/10.1039/b701677h).
173. Roughley, S. D., & Jordan, A. M. The Medicinal Chemist’s Toolbox: an analysis of reactions used in the pursuit of drug candidates. *J. Med. Chem.*, **2011**, 54(10), 3451–3479. DOI: [10.1021/jm200187y](https://doi.org/10.1021/jm200187y).
174. Supuran, C. T., Briganti, F., Tilli, S., Chegwidan, W., & Scozzafava, A. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? *Bioorg. Med. Chem.*, **2001**, 9(3), 703–714. DOI: [10.1016/s0968-0896\(00\)00288-1](https://doi.org/10.1016/s0968-0896(00)00288-1).

175. Kumari, A., & Singh, R. K. Medicinal chemistry of indole derivatives: Current to future therapeutic perspectives. *Bioorg. Chem.*, **2019**, 89, 103021. DOI: [10.1016/j.bioorg.2019.103021](https://doi.org/10.1016/j.bioorg.2019.103021).
176. Fatahala, S. S., Hasabelnaby, S., Goudah, A., Mahmoud, G., & Hameed, R. H. A. Pyrrole and Fused Pyrrole Compounds with Bioactivity against Inflammatory Mediators. *Molecules*, **2017**, 22(3), 461–472. DOI: [10.3390/molecules22030461](https://doi.org/10.3390/molecules22030461).
177. Manya, B. S., Kumar, M. R. P., Rajagopal, K., Hassan, M. A., Rab, S. O., Alshehri, M. A., & Emran, T. B. Insights into the Biological Activities and Substituent Effects of Pyrrole Derivatives: The Chemistry-Biology Connection. *Chem. Biodivers.*, **2024**, 21(8). DOI: [10.1002/cbdv.202400534](https://doi.org/10.1002/cbdv.202400534).
178. Chang, L., Li, C., Qin, N., Jin, M., & Duan, H. Synthesis and antidiabetic activity of 5,7-Dihydroxyflavonoids and analogs. *Chem. Biodivers.*, **2012**, 9(1), 162–169. DOI: [10.1002/cbdv.201100049](https://doi.org/10.1002/cbdv.201100049).
179. Long, L., Zhang, H., Zhou, Z., Duan, L., Fan, D., Wang, R., Xu, S., Qiao, D., & Zhu, W. Pyrrole-containing hybrids as potential anticancer agents: An insight into current developments and structure-activity relationships. *Eur. J. Med. Chem.*, **2024**, 273, 116470. DOI: [10.1016/j.ejmech.2024.116470](https://doi.org/10.1016/j.ejmech.2024.116470).
180. Cakmak, S., Yenigun, S., & Ozen, T. Preparation, structural analysis, bioactivity assessment, enzyme and molecular docking calculations of some furan/thiophene-2-carboxamide derivatives. *J. Iran. Chem. Soc.*, **2023**, 20(10), 2543–2553. DOI: [10.1007/s13738-023-02852-4](https://doi.org/10.1007/s13738-023-02852-4).
181. Owczarek-Fendor, A., De Meulenaer, B., Scholl, G., Adams, A., Van Lancker, F., Eppe, G., De Pauw, E., Scippo, M., & De Kimpe, N. Furan Formation from Lipids in Starch-Based Model Systems, As Influenced by Interactions with Antioxidants and Proteins. *J. Agric. Food Chem.*, **2011**, 59(6), 2368–2376. DOI: [10.1021/jf103168s](https://doi.org/10.1021/jf103168s).
182. Chen, P., Tsai, W., Ueng, Y., Tzeng, T., Chen, H., Zhu, P., Huang, C., Shiao, Y., & Li, W. Neuroprotective and Antineuroinflammatory Effects of Hydroxyl-Functionalized Stilbenes and 2-Arylbenzo[b]furans. *J. Med. Chem.*, **2017**, 60(9), 4062–4073. DOI: [10.1021/acs.jmedchem.7b00376](https://doi.org/10.1021/acs.jmedchem.7b00376).
183. Dazie, J. D., Liska, A., Ludvik, J., Fabry, J., Dusek, M., & Eigner, V. Planarity of substituted pyrrole and furan rings in (3R, 1'S, 3'R)-3-(1'-tert-butylamino-1'H, 3' H-benzo[c]furan-3'-yl)-2-tert-butyl-2,3-dihydro-1H-benzo[c]pyrrol-1-

- one. *Zeitschrift Fur Kristallographie – Cryst. Mater.*, **2017**, 232(6), 441–452. DOI: [10.1515/zkri-2016-2001](https://doi.org/10.1515/zkri-2016-2001).
184. Pibiri, I. Recent Advances: Heterocycles in Drugs and Drug Discovery. *Int. J. Mol. Sci.*, **2024**, 25(17), 9503. DOI: [10.3390/ijms25179503](https://doi.org/10.3390/ijms25179503).
 185. Schmidt, A. W., Lebel, L. A., Howard, H. R., & Zorn, S. H. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. *Eur. J. Pharmacol.*, **2001**, 425(3), 197–201. DOI: [10.1016/s0014-2999\(01\)01188-8](https://doi.org/10.1016/s0014-2999(01)01188-8).
 186. Mathada, B. S., Yernale, N. G., Basha, J. N., & Badiger, J. An insight into the advanced synthetic recipes to access ubiquitous indole heterocycles. *Tetrahedron Lett.*, **2021**, 85, 153458. DOI: [10.1016/j.tetlet.2021.153458](https://doi.org/10.1016/j.tetlet.2021.153458).
 187. Eid, P. S., Ibrahim, D. A., Zayan, A. H., Elrahman, M. M. A., Shehata, M. a. A., Kandil, H., Abouibrahim, M. A., Duy, L. M., Shinkar, A., Elfaituri, M. K., Minh, L. H. N., Fahmy, M. M., Tam, D. N. H., Vuong, N. L., Shah, J., Dan, V. B., DO, Hirayama, K., & Huy, N. T. Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials. *Heart Fail. Rev.*, **2020**, 26(1), 127–136. DOI: [10.1007/s10741-020-10003-7](https://doi.org/10.1007/s10741-020-10003-7).
 188. Vittori, S., Ben, D. D., Lambertucci, C., Marucci, G., Volpini, R., & Cristalli, G. Antiviral properties of deazaadenine nucleoside derivatives. *Curr. Med. Chem.*, **2006**, 13(29), 3529–3552. DOI: [10.2174/092986706779026228](https://doi.org/10.2174/092986706779026228).
 189. Ivan, B., Barbuceanu, S., Hotnog, C. M., Anghel, A. I., Ancuceanu, R. V., Mihaila, M. A., Brasoveanu, L. I., Shova, S., Draghici, C., Olaru, O. T., Nitulescu, G. M., Dinu, M., & Dumitrascu, F. New pyrrole derivatives as promising biological agents: design, synthesis, characterization, in silico, and cytotoxicity evaluation. *Int. J. Mol. Sci.*, **2022**, 23(16), 8854. DOI: [10.3390/ijms23168854](https://doi.org/10.3390/ijms23168854).
 190. Turan, A., Karamanlyoglu, B., Memis, D., Kaya, G., & Pamuksu, Z. Intravenous regional anesthesia using prilocaine and neostigmine. *Anesth. Analg.*, **2002**, 95(5), 1419–1422. DOI: [10.1097/00000539-200211000-00058](https://doi.org/10.1097/00000539-200211000-00058).
 191. Scott, L. J., & Perry, C. M. Delavirdine. *Drugs*, **2000**, 60(6), 1411–1444. DOI: [10.2165/00003495-200060060-00013](https://doi.org/10.2165/00003495-200060060-00013).
 192. Mathew, N. T. Naratriptan: a review. *Expert Opin. Investig. Drugs*, **1999**, 8(5), 687–695. DOI: [10.1517/13543784.8.5.687](https://doi.org/10.1517/13543784.8.5.687).

193. Zhang, Z., Gu, J., Ji, L., Liu, X., Zhang, T., Lv, Y., Liu, F., Jia, Z., & Loh, T. Triaryl carbonium Ion-Pair-Mediated cooperative aerobic dehydrogenation of *N*-Heterocycles. *ACS Catal.*, **2022**, 12(22), 14123–14129. DOI: [10.1021/acscatal.2c04010](https://doi.org/10.1021/acscatal.2c04010).
194. Volk, B., Berecz, G., Dancsó, A., Németh, D. R., Kiss, L., & Simig, G. Towards Tianeptine Analogues: Synthesis of New Ring Systems Containing a Dibenzo[*c,f*][1,2]thiazepine S,S-Dioxide Core. *Synthesis*, **2022**, 54(17), 3874–3882. DOI: [10.1055/s-0040-1719885](https://doi.org/10.1055/s-0040-1719885).
195. Kolade, S. O., Izunobi, J. U., Gordon, A. T., Hosten, E. C., Olasupo, I. A., Ogunlaja, A. S., Asekun, O. T., & Familoni, O. B. *N*-Cycloamino substituent effects on the packing architecture of ortho-sulfanilamide molecular crystals and their in silico carbonic anhydrase II and IX inhibitory activities. *Acta Crystallogr. Sect. C Struct. Chem.*, **2022**, 78(12), 730–742. DOI: [10.1107/s2053229622010130](https://doi.org/10.1107/s2053229622010130).
196. Kolade, S. O., Aina, O. S., Gordon, A. T., Hosten, E. C., Olasupo, I. A., Ogunlaja, A. S., Asekun, O. T., & Familoni, O. B. Synthesis, crystal structure and in-silico evaluation of arylsulfonamide Schiff bases for potential activity against colon cancer. *Acta Crystallogr. Sect. C Struct. Chem.*, **2024**, 80(4), 129–142. DOI: [10.1107/s205322962400233x](https://doi.org/10.1107/s205322962400233x).
197. Ho, C. Y., Strobel, E., Ralbovsky, J., & Galemno, R. A. Improved Solution- and Solid-Phase Preparation of Hydroxamic Acids from Esters. *J. Org. Chem.*, **2005**, 70(12), 4873–4875. DOI: [10.1021/jo050036f](https://doi.org/10.1021/jo050036f).
198. Li, D., Chen, Y., Ma, M., Yu, Y., Jia, Z., Li, P., & Xie, Z. Regioselective C5 nitration of *N*-protected indolines using ferric nitrate under mild conditions. *Synth. Commun.*, **2019**, 49(10), 1231–1240. DOI: [10.1080/00397911.2019.1580745](https://doi.org/10.1080/00397911.2019.1580745).
199. Hlasta, D. J., Luttinger, D., Perrone, M. H., Silbernagel, M. J., Ward, S. J., & Haubrich, D. R. α .2-Adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines. *J. Med. Chem.*, **1987**, 30(9), 1555–1562. DOI: [10.1021/jm00392a005](https://doi.org/10.1021/jm00392a005).
200. You, Y., Kanna, W., Takano, H., Hayashi, H., Maeda, S., & Mita, T. Electrochemical Dearomative Dicarboxylation of Heterocycles with Highly

- Negative Reduction Potentials. *J. Am. Chem. Soc.*, **2022**, *144*(8), 3685–3695. DOI: [10.1021/jacs.1c13032](https://doi.org/10.1021/jacs.1c13032).
201. Jiang, B., Hu, J., Liu, H., Liu, Z., Wen, Y., Liu, M., Zhang, H., Pang, X., & Yu, L. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. *Eur. J. of Med. Chem.*, **2021**, *227*, 113893. DOI: [10.1016/j.ejmech.2021.113893](https://doi.org/10.1016/j.ejmech.2021.113893).
 202. Ahmad, A., Sakr, W. A., & Rahman, K. W. (2010). Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. *Curr. Drug Targets*, **2010**, *11*(6), 652–666. DOI: [10.2174/138945010791170923](https://doi.org/10.2174/138945010791170923).
 203. Kuzovlev, A. S., Zybalov, M. D., Golovin, A. V., Gureev, M. A., Kasatkina, M. A., Biryukov, M. V., Belik, A. R., Silonov, S. A., Yunin, M. A., Zigangirova, N. A., Reshetnikov, V. V., Isakova, Y. E., Porozov, Y. B., & Ivanov, R. A. Naphthyl-Substituted indole and pyrrole carboxylic acids as effective Antibiotic Potentiators-Inhibitors of bacterial cystathionine Γ -Lyase. *Int. J. of Mol. Sci.*, **2023**, *24*(22), 16331. DOI: [10.3390/ijms242216331](https://doi.org/10.3390/ijms242216331).
 204. Peerzada, M. N., Khan, P., Ahmad, K., Hassan, M. I., & Azam, A. Synthesis, characterization and biological evaluation of tertiary sulfonamide derivatives of pyridyl-indole based heteroaryl chalcone as potential carbonic anhydrase IX inhibitors and anticancer agents. *Eur. J. Med. Chem.*, **2018**, *155*, 13–23. DOI: [10.1016/j.ejmech.2018.05.034](https://doi.org/10.1016/j.ejmech.2018.05.034).
 205. Jia, B., Ma, Y., Liu, B., Chen, P., Hu, Y., & Zhang, R. Synthesis, antimicrobial activity, Structure-Activity relationship, and molecular docking studies of indole diketopiperazine alkaloids. *Front. Chem.*, **2019**, *7*. DOI: [10.3389/fchem.2019.00837](https://doi.org/10.3389/fchem.2019.00837).
 206. Bhat, R. M., Hegde, V., Budagumpi, S., Adimule, V., & Keri, R. S. Benzimidazole–Oxadiazole Hybrids—Development in Medicinal Chemistry: An Overview. *Chem. Biol. Drug Des.*, **2024**, *104*(2). DOI: [10.1111/cbdd.14609](https://doi.org/10.1111/cbdd.14609).
 207. Khan, S., Iqbal, T., Hussain, R., Khan, Y., Fiaz, Z., Rahim, F., & Darwish, H. W. Synthesis, characterizations, Anti-Diabetic and molecular modeling approaches of hybrid Indole-Oxadiazole linked thiazolidinone derivatives. *Pharm.*, **2024**, *17*(11), 1428. DOI: [10.3390/ph17111428](https://doi.org/10.3390/ph17111428).

208. Zheng, S., Jiang, Q., Massande, G. N., Wu, W., Lin, C., Fang, Y., Tan, Y., & Zhu, R. Synthesis and antifungal activity of indole derivatives. *Chem. Nat. Compd.*, **2023**, 59(1), 111–118. DOI: [10.1007/s10600-023-03929-5](https://doi.org/10.1007/s10600-023-03929-5).
209. Jones, G. B., Heaton, S. B., Chapman, B. J., & Guzel, M. On the origins of enantioselectivity in oxazaborolidine mediated carbonyl reductions. *Tetrahedron Asym.*, **1997**, 8(21), 3625–3636. DOI: [10.1016/s0957-4166\(97\)00497-7](https://doi.org/10.1016/s0957-4166(97)00497-7).
210. Pant, S. M., Mukonoweshuro, A., Desai, B., Ramjee, M. K., Selway, C. N., Tarver, G. J., Wright, A. G., Birchall, K., Chapman, T. M., Tervonen, T. A., & Klefström, J. Design, synthesis, and testing of potent, selective hepsin inhibitors via application of an automated Closed-Loop optimization platform. *J. Med. Chem.*, **2018**, 61(10), 4335–4347. DOI: [10.1021/acs.jmedchem.7b01698](https://doi.org/10.1021/acs.jmedchem.7b01698).
211. Thompson, J. C., Dao, W. T., Ku, A., Rodriguez-Beltran, S. L., Amezcua, M., Palomino, A. Y., Lien, T., & Salzameda, N. T. Synthesis and activity of isoleucine sulfonamide derivatives as novel botulinum neurotoxin serotype A light chain inhibitors. *Bioorg. Med. Chem.*, **2020**, 28(18), 115659. DOI: [10.1016/j.bmc.2020.115659](https://doi.org/10.1016/j.bmc.2020.115659).
212. Theodorou, V., Skobridis, K., Tzakos, A. G., & Ragoussis, V. A simple method for the alkaline hydrolysis of esters. *Tetrahedron Lett.*, **2007**, 48(46), 8230–8233. DOI: [10.1016/j.tetlet.2007.09.074](https://doi.org/10.1016/j.tetlet.2007.09.074).
213. Yan, S., Appleby, T., Gunic, E., Shim, J. H., Tasu, T., Kim, H., Rong, F., Chen, H., Hamatake, R., Wu, J. Z., Hong, Z., & Yao, N. Isothiazoles as active-site inhibitors of HCV NS5B polymerase. *Bioorg. Med. Chem. Lett.*, **2006**, 17(1), 28–33. DOI: [10.1016/j.bmcl.2006.10.002](https://doi.org/10.1016/j.bmcl.2006.10.002).
214. Paillet-Loilier, M., Fabis, F., Lepailleur, A., Bureau, R., Butt-Gueulle, S., Dauphin, F., Delarue, C., Vaudry, H., & Rault, S. Phenylpyrroles, a new chemolibrary virtual screening class of 5-HT7 receptor ligands. *Bioorg. Med. Chem. Lett.*, **2005**, 15(16), 3753–3757. DOI: [10.1016/j.bmcl.2005.05.059](https://doi.org/10.1016/j.bmcl.2005.05.059).
215. Juneja, T., Chakraborty, J., Kapadiya, K., & Kamdar, J. H. Identification of Phytochemical Inhibitors Targeting VEGFA and TGFBR2 of Cervical Cancer: Insights from Virtual Screening, ADMET and DFT Studies. *ChemistrySelect*, **2024**, 9(17). DOI: [10.1002/slct.202304901](https://doi.org/10.1002/slct.202304901).
216. Shah, A., Teraiya, N., Kamdar, J. H., Juneja, T., Sangani, C. B., Ahmed, S., & Kapadiya, K. Novel purine derivatives as selective CDK2 inhibitors with

- potential anticancer activities: Design, synthesis and biological evaluation. *Bioorg. Chem.*, **2024**, *153*, 107841. DOI: [10.1016/j.bioorg.2024.107841](https://doi.org/10.1016/j.bioorg.2024.107841).
217. Bakchi, B., Krishna, A. D., Sreecharan, E., Ganesh, V. B. J., Niharika, M., Maharshi, S., Puttagunta, S. B., Sigalapalli, D. K., Bhandare, R. R., & Shaik, A. B. An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist's perspective. *J. Mol. Struct.*, **2022**, *1259*, 132712. DOI: [10.1016/j.molstruc.2022.132712](https://doi.org/10.1016/j.molstruc.2022.132712).
 218. Jatiya, J. N., Patel, A. S., & Savant, M. M. Synthesis, *in vitro* antimicrobial evaluation, ADMET properties, and molecular docking studies of novel thiazole derivatives. *Russ. J. Gen. Chem.*, **2023**, *93*(10), 2621–2631. DOI: [10.1134/s107036322310016x](https://doi.org/10.1134/s107036322310016x).
 219. Bhatt, V., Samant, S. D., & Pednekar, S. Efficient one-pot HATU mediated coupling of dicarboxylic acid and amines for the synthesis of diamide at ambient temperature. *Lett. Org. Chem.*, **2017**, *14*(10). DOI: [10.2174/1570178614666170710095437](https://doi.org/10.2174/1570178614666170710095437).
 220. Kunin, C. M., & Ellis, W. Y. Antimicrobial activities of mefloquine and a series of related compounds. *Antimicrobial Agents and Chemotherapy*, **2000**, *44*(4), 848–852. DOI: [10.1128/aac.44.4.848-852.2000](https://doi.org/10.1128/aac.44.4.848-852.2000).
 221. Modasiya, J. B., Kamdar, J. H., Kapadiya, K. M., Gundaraniya, S., & George, J. J. A computational approach to finding novel drug targets and their natural product inhibitors for *Aspergillus flavus*. In *Elsevier eBooks* **2023**, 219–231. DOI: [10.1016/b978-0-443-15457-7.00020-4](https://doi.org/10.1016/b978-0-443-15457-7.00020-4).
 222. Ferreira, L. G., Santos, R. N. D., Oliva, G., & Andricopulo, A. D. Molecular Docking and Structure-Based drug design Strategies. *Molecules*, **2015**, *20*(7), 13384–13421. DOI: [10.3390/molecules200713384](https://doi.org/10.3390/molecules200713384).
 223. Adasme, M. F., Linnemann, K. L., Bolz, S. N., Kaiser, F., Salentin, S., Haupt, V. J., & Schroeder, M. PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA. *Nucleic Acids Res.*, **2021**, *49*(W1), W530–W534. DOI: [10.1093/nar/gkab294](https://doi.org/10.1093/nar/gkab294).
 224. Childers, M. C., & Daggett, V. Insights from molecular dynamics simulations for computational protein design. *Mol. Syst. Design Eng.*, **2017**, *2*(1), 9–33. DOI: [10.1039/c6me00083e](https://doi.org/10.1039/c6me00083e).

225. Daina, A., Michielin, O., & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*, **2017**, 7(1). DOI: [10.1038/srep42717](https://doi.org/10.1038/srep42717).
226. Yang, H., Lou, C., Sun, L., Li, J., Cai, Y., Wang, Z., Li, W., Liu, G., & Tang, Y. admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. *Bioinformatics*, **2018**, 35(6), 1067–1069. DOI: [10.1093/bioinformatics/bty707](https://doi.org/10.1093/bioinformatics/bty707).
227. Mathakiya, A., Patel, B., Raval, K., Kamdar, J. H., Sharma, S., & Dhalani, J. Novel pyridine-1,3,4-oxadiazole linked 1,2,3-triazole hybrids: synthesis, molecular docking, ADME, DFT study and anti-tumor potential. *Results Chem.*, **2025**, 102521. DOI: [10.1016/j.rechem.2025.102521](https://doi.org/10.1016/j.rechem.2025.102521).
228. Karoui, S., Khaoua, O., Benbellat, N., Antonczak, S., & Messaoudi, A. Molecular Docking, Molecular Dynamics, PKCSM Drug-Likeness Profiles, Toxicity, and DFT study of the antioxidant and anticancer activities of three flavonoid derivatives. *ChemistrySelect*, **2024**, 9(40). DOI: [10.1002/slct.202401776](https://doi.org/10.1002/slct.202401776).
229. Fu, L., Shi, S., Yi, J., Wang, N., He, Y., Wu, Z., Peng, J., Deng, Y., Wang, W., Wu, C., Lyu, A., Zeng, X., Zhao, W., Hou, T., & Cao, D. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. *Nucleic Acids Res.*, **2024**, 52(W1), W422–W431. DOI: [10.1093/nar/gkae236](https://doi.org/10.1093/nar/gkae236).

Plagiarism Report






The Report is Generated by DrillBit Plagiarism Detection Software

Submission Information

Author Name	Ajay Jani
Title	Synthesis, Characterization and Biological Evaluation of Some Fused Heterocyclic Derivatives
Paper/Submission ID	4285305
Submitted by	director.rit@atmiyauni.ac.in
Submission Date	2025-08-28 09:09:45
Total Pages, Total Words	320, 53514
Document type	Thesis

Result Information

Similarity **7 %**



Exclude Information

Quotes	Excluded	Language	English
References/Bibliography	Excluded	Student Papers	Yes
Source: Excluded < 1 Words	Excluded	Journals & publishers	Yes
Excluded Source	0 %	Internet or Web	Yes
Excluded Phrases	Excluded	Institution Repository	Yes

Database Selection

A Unique QR Code use to View/Download/Share Pdf File



Publications

1) ChemistrySelect

Jani, A. J., Ghoshal, T., Ameta, R. K., Teraiya, N., Tala, S. D. Synthesis, *in vitro* antiproliferative activity, and in silico studies of Indole–Piperidine hybrids bearing amide and urea linkages. *ChemistrySelect*, **2025**, *10*(23), e01370 (1-19).
<https://doi.org/10.1002/slct.202501370>.



Scopus Preview

Source details

ChemistrySelect

Years currently covered by Scopus: from 2016 to 2025

Publisher: John Wiley & Sons

E-ISSN: 2365-6549

Subject area: Chemistry: General Chemistry

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

CiteScore

CiteScore rank & trend

Scopus content coverage

CiteScore 2024



$$3.0 = \frac{24,390 \text{ Citations } 2021 - 2024}{8,238 \text{ Documents } 2021 - 2024}$$

Calculated on 05 May, 2025

CiteScoreTracker 2025 ⓘ

$$2.7 = \frac{22,114 \text{ Citations to date}}{8,178 \text{ Documents to date}}$$

Last updated on 05 July, 2025 • Updated monthly

CiteScore rank 2024 ⓘ

Category

Rank Percentile

Chemistry

General Chemistry

#219/404

45th

Editor-in-Chief: Jos Lenders;

Deputy Editor: Pilar Calleja Ramos, Katja Glatz;

Editorial Board Chairs: Dennis Hetterscheid, Hélène Lebel, An-Hui Lu

Online ISSN: 2365-6549

Print ISSN: 2365-6549

© Wiley-VCH GmbH, Weinheim

As a leading sound science journal in the field, *ChemistrySelect* offers a platform for original authoritative research in all areas of chemistry. We support the community with a stable foundation of reliable chemistry research. Submit your paper and add value to the collective knowledge of the field.

Journal Metrics

3

CiteScore

2

Journal Impact Factor

45%

Acceptance Rate

33 days

Submission To First
Decision

Synthesis, In Vitro Antiproliferative Activity, and In Silico Studies of Indole–Piperidine Hybrids Bearing Amide and Urea Linkages

Ajay J. Jani,^[a, b] Tanay Ghoshal,^[c] Rakesh Kumar Ameta,^[d] Nishith Teraiya,^[e] and Satishkumar D. Tala^{*[a]}

The present study described the synthesis and anticancer activity of new indole–piperidine hybrids functionalized with piperidin-4-yl-benzamide (9a–n) and piperidin-4-yl-urea (11a–g, 13a–f) moieties. All the newly synthesized compounds were purified by reverse phase flash chromatography and characterized by FTIR, ¹H and ¹³C NMR, LC–MS, and elemental analysis. Their in vitro anticancer activity was tested against the NCI-60 human tumor cell lines (National Cancer Institute, USA). The results revealed that compounds 9c, 11d, 13b, and 13e were found active

against UO-31 (renal cancer) having growth (%) as –22.98%, –49.98%, –83.76%, and –82.75%, respectively. While compound 11f exhibited notable activity against RPMI-8226 (leukemia) and MDA-MB-468 (breast cancer). Moreover, in silico docking studies revealed effective VEGFR-2 binding with the receptor and formed stable protein–ligand complex with low docking scores. Additionally, drug-likeness and ADMET predictions indicated favorable pharmacokinetic profiles with no associated toxicity concerns.

1. Introduction

Cancer, a disease characterized by pathological proliferation of malignant cells, is the second leading cause of death worldwide.^[1] Despite the development of numerous anticancer agents, drug resistance and adverse side effects remain significant challenges.^[2] Amongst the various cancer types, leukemia, renal cancer, and breast cancer are categorized into major molecular subtypes based on hormone and growth factor receptor expression.^[3] The limitations of current treatments contribute to the high mortality rate associated with breast cancer, highlighting the need for novel antineoplastic drugs to address these challenges.^[4] Although several cancer therapies have been approved globally, the emergence of resistance underscores the ongoing demand for medications that can overcome this obstacle.

In anticancer drug discovery, heterocyclic compounds are key constituents of numerous pharmacological active molecules and are present in over 80% of FDA-approved medications.^[5] These compounds exert their bioactivity by inhibiting specific genes, enzymes, and receptors to provide protection against cancer. Based on their biochemical modes of action and suitability for cancer therapy, the FDA approved several heterocyclic derivatives in 2024 that exhibit physiological activity against various types of cancer growths.^[6] Particularly, hybrid heterocycles containing two active pharmacophores are being increasingly explored due to their ability to interact with multiple receptors with high affinity. These hybrid structures are frequently found in various pharmacologically active compounds. Among them, indole based heterocycles are considered one of the most significant structural classes in drug development.^[7,8] In medicinal chemistry, indole and its analogs are being rapidly identified, because of diverse synthetic methodologies and abundant natural sources.^[9] Several indole derivatives containing a piperidine moiety have shown promising biological activities, including antidepressant (Indalpine, 1),^[10] antiviral (Ajmalicine, 2),^[11] anti-inflammatory (3), antitubercular (4),^[12] anticancer (Mitraphylline, 5),^[13] antioxidant (6), antidiabetic (7),^[14] antidepressants (Mitragynine, 8),^[15] anti-HIV (Atevirdine, 9),^[16] Delavirdine, 10^[17], antitumorogenic (Brivanib, 11)^[18] activities. Notably, in recent years, several indole-based molecules such as Tadalafil (12),^[19] Alectinib (13),^[20] Apaziquinone (14), and Panobinostat (15),^[21] (Figure 1) have been approved for the treatment of various cancers, demonstrating their potential as leads for new anticancer drug development.

Indole derivatives featuring various functional groups and amide linkages have been well reported as histamine H₁-receptor antagonists,^[22] enzyme inhibitors,^[23] and agents with antiproliferative activity.^[24] Moreover, inspired from the structural for-

[a] A. J. Jani, S. D. Tala
Department of Chemistry, Atmiya University, Rajkot, Gujarat 360005, India
E-mail: satish.tala@atmiyauni.ac.in

[b] A. J. Jani
Piramal Pharma Solution, Ahmedabad, Gujarat 382213, India

[c] T. Ghoshal
Shri MM Patel Institute of Sciences and Research, Department of Chemistry,
Kadi Sarva Vishwavidyalaya, Gandhinagar, Gujarat 382023, India

[d] R. K. Ameta
Department of Chemistry, Gandhinagar Institute of Science, Gandhinagar
University, Gandhinagar, Gujarat 382023, India

[e] N. Teraiya
Department of Pharmaceutical Chemistry, K B Institute of Pharmaceutical
Education and Research, Kadi Sarva Vishwavidyalaya, Gandhinagar, Gujarat
382023, India

Supporting information for this article is available on the WWW under
<https://doi.org/10.1002/slct.202501370>

2) *Synthetic Communications* (Taylor & Francis)

Jani, A. J., Kamdar, J. H., Tala, S. D. Design, synthesis, antimicrobial evaluation, in-silico molecular docking, and ADME-T evaluation of novel benzoxazole-piperazine hybrids with amide linkage. *Synthetic Communications*, **2025**, 55(16), 1228–1246. DOI: <https://doi.org/10.1080/00397911.2025.2535655>.



Scopus Preview



Source details

Synthetic Communications

Years currently covered by Scopus: from 1971 to 2025

Publisher: Taylor & Francis

ISSN: 0039-7911 E-ISSN: 1532-2432

Subject area: [Chemistry: Organic Chemistry](#)

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

CiteScore 2024

4.3



SJR 2024

0.322



SNIP 2024

0.560



[CiteScore](#) [CiteScore rank & trend](#) [Scopus content coverage](#)

CiteScore 2024

4.3 = $\frac{3,231 \text{ Citations } 2021 - 2024}{759 \text{ Documents } 2021 - 2024}$

Calculated on 05 May, 2025

CiteScoreTracker 2025

3.0 = $\frac{1,693 \text{ Citations to date}}{558 \text{ Documents to date}}$

Last updated on 05 August, 2025 • Updated monthly

[CiteScore rank 2024](#)

Synthetic Communications

[Aims and scope](#)

[Journal metrics](#)

[Editorial board](#)

[Abstracting and indexing](#)

[Open access](#)

[Publication details](#)

[Advertising information](#)

Journal metrics



Usage

- **369K** annual downloads/views



Citation metrics

- **1.8 (2024)** Impact Factor
- **1.9 (2024)** 5 year IF
- **4.3 (2024)** CiteScore (Scopus)
- **0.560 (2024)** SNIP
- **0.322 (2024)** SJR



Speed/acceptance

- **1** days avg. from submission to first decision
- **30** days avg. from submission to first post-review decision
- **11** days avg. from acceptance to online publication



Design, synthesis, antimicrobial evaluation, in-silico molecular docking, and ADME-T evaluation of novel benzoxazole-piperazine hybrids with amide linkage

Ajay J. Jani^{a,b}, Jignesh H. Kamdar^c and Satishkumar D. Tala^{a*}

^aDepartment of Chemistry, Atmiya University, Rajkot, India; ^bPiramal Pharma Solution, Ahmedabad, India/Gujarat; ^cIn-silico lab, Department of Microbiology, School of Science, RK University, Rajkot, India

ABSTRACT

A series of benzoxazole-piperazine hybrids (**9a–n**) has been synthesized via a multistep approach incorporating the Mitsunobu reaction. These compounds were obtained in good yields using cost-effective and readily available starting materials under mild reaction conditions. Structural characterization was performed using ¹H NMR, ¹³C NMR, LCMS, elemental analysis, and FTIR spectroscopy. The antimicrobial potential of **9a–n** was assessed against bacterial strains *Bacillus subtilis*, *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *Escherichia coli* and fungal strains *Aspergillus niger*, and *Candida albicans*. Notably, compounds **9b**, **9c** and **9f** exhibited potent antibacterial activity, comparable to chloramphenicol and gentamicin, and antifungal activity similar to nystatin. Molecular docking and dynamics simulations suggested that **9f** inhibits *E. coli* DNA gyrase, forming a stable protein-ligand complex with strong binding interactions and low docking scores. Furthermore, in silico ADMET analysis indicated favorable pharmacokinetic properties with no significant toxicity concerns, highlighting their potential as promising antimicrobial agents.

GRAPHICAL ABSTRACT



ARTICLE HISTORY

Received 13 March 2025

KEYWORDS

ADMET study;
anti-microbial activity;
benzoxazole; hybri-
de compounds; molecu-
lar docking

Introduction

Sixty percent of the earth's biomass is impacted by microbial pathogenic diseases, posing a serious threat to global health.^[1] The World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the top ten global health threats.^[2] Resistant strains of pathogens, such as *Staphylococcus aureus*, *Escherichia coli*, *Bacillus*

CONTACT Satishkumar D. Tala satishtrada@gmail.com Department of Chemistry, Atmiya University, Kalawad Road, Rajkot-360005, Gujarat, India.

^aPresent address: SNJ Labs Pvt. Ltd., Padavala-360024, Gujarat, India.

Supplemental data for this article can be accessed online at <https://doi.org/10.1080/00397911.2025.2535655>.

© 2025 Taylor & Francis Group, LLC

3) Chemistry & Biodiversity (Under revision)

Jani, A. J., Kamdar, J. H., Tala, S. D. Targeted Synthesis, *In Vitro* Antimicrobial Profiling and *In Silico* Studies of Furan and Pyrrole Linked Indoline Hybrids Incorporating Amide and Sulfonamide Linkages. *Chemistry & Biodiversity* (Wiley-VCHA), 2025, Manuscript ID: *cbdv.202501677R1*.

List of Seminar/Conference Participated

- 1) Online conference on “Research Methodology” by Udemy on 26th May 2021.




- 2) One week workshop on “copyright, patentfilling and journal indexing” organized by REST Society for Research International (RSRI) Krishnagiri, Tamilnadu, India 7th- 11th June 2021.



- 3) Online course on “Learning fundamentals of publishing in quality journals” by Elsevier on 26th May 2021.



- 4) Conference: “International virtual conference on frontiers” organised by Department of Chemistry MLSU, Udaipur, Rajasthan, India on 25th June, 2021.



- 5) 2nd International conference on Emerging Trends & Contemporary Practices- ICETCP 2024” hosted by Atmiya University, Rajkot, India on 9-10th Feb 2024.

